Daratumumab Prolongs Survival Compared with Standard of Care in Patients with Heavily Pretreated and Highly Refractory Multiple Myeloma

Conference Correspondent  - Conference Correspondent, ASH

In comparing real-world outcomes associated with standard-of-care therapies and outcomes achieved with daratumumab monotherapy in clinical trials, daratumumab was found to extend overall survival (OS) in patients with heavily pretreated and highly refractory multiple myeloma (MM).

Kumar and colleagues performed adjusted comparisons of the effectiveness of daratumumab monotherapy versus real-world standard-of-care therapies. To perform this comparison, they used data for patients treated with daratumumab monotherapy from 2 clinical trials: MMY2002 (n = 106) and GEN501 (n = 42). Patients treated with standard-of-care therapies were derived from the International Myeloma Foundation (IMF) chart review of patients with MM who had ≥3 prior lines of therapy and were double-refractory to a proteasome inhibitor and an immunomodulatory drug (n = 543).

In pooling the data from the 2 daratumumab trials, daratumumab demonstrated a median OS of 20.1 months. By comparison, the IMF cohort had a median OS of only 13.0 months.

Using 2 adjusted comparison methodologies, propensity score matching (PSM) and multivariate Cox regression analyses, they found a significant difference in OS in favor of daratumumab. After PSM, a 54% improvement in OS was found in favor of daratumumab relative to standard of care (hazard ratio [HR], 0.44; 95% confidence interval [CI], 0.31-0.63). After adjustment for differences in covariates included in the regression analysis, OS again was found to be significantly superior with daratumumab compared with standard of care (HR, 0.43; 95% CI, 0.32-0.59).

The researchers determined that the findings from the PSM and regression analyses were consistent, and suggest that daratumumab is associated with significant gains in OS compared with standard-of-care therapies in this patient population.

Kumar SK, et al. ASH 2016. Abstract 4517.

Related Items
No Link between Long-Term Eltrombopag Treatment and Incidence of Cataracts in Adult Patients with Chronic ITP During EXTEND
Conference Correspondent  published on December 27, 2017 in ASH
Eltrombopag Treatment Improved Platelet Counts in Patients with Persistent or Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Fostamatinib-Treated Patients with Persistent/Chronic ITP Maintained Long-Term Responses
Conference Correspondent  published on December 27, 2017 in ASH
Avatrombopag Superior to Placebo for the Treatment of Chronic ITP
Conference Correspondent  published on December 27, 2017 in ASH
Subcutaneous Romiplostim Increased Platelet Response in Children with ITP
Conference Correspondent  published on December 27, 2017 in ASH
Centers for Disease Control and Prevention Guidelines on Opioid Use for Cancer Pain
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Maintenance Chemotherapy After Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Graft-versus-Host Disease: Breakthroughs on the Horizon
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Basket Clinical Trials: A New Era in Cancer Treatment
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Burnout Rates High for Pharmacists in Hematopoietic Stem-Cell Transplantation
Chase Doyle
TOP - August 2017, Vol 10, No 3 published on August 1, 2017 in Conference Correspondent, HOPA
Last modified: December 5, 2017